1.93
4.89%
+0.09
Pre-market:
1.89
-0.04
-2.07%
ATAI Life Sciences N.V. stock is currently priced at $1.93, with a 24-hour trading volume of 875.09K.
It has seen a +4.89% increased in the last 24 hours and a +11.56% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $1.86 pivot point. If it approaches the $1.97 resistance level, significant changes may occur.
Previous Close:
$1.84
Open:
$1.85
24h Volume:
875.09K
Market Cap:
$323.11M
Revenue:
$314.00K
Net Income/Loss:
$-40.23M
P/E Ratio:
-2.0978
EPS:
-0.92
Net Cash Flow:
$-84.71M
1W Performance:
+4.32%
1M Performance:
+11.56%
6M Performance:
+69.30%
1Y Performance:
+3.21%
ATAI Life Sciences N.V. Stock (ATAI) Company Profile
Name
ATAI Life Sciences N.V.
Sector
Industry
Phone
49 89 2153 9035
Address
Krausenstrasse 9-10, Berlin
ATAI Life Sciences N.V. Stock (ATAI) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Nov-01-22 | Initiated | Loop Capital | Buy |
Nov-30-21 | Initiated | Maxim Group | Buy |
Nov-11-21 | Initiated | ROTH Capital | Buy |
Oct-18-21 | Initiated | H.C. Wainwright | Buy |
Sep-01-21 | Initiated | Jefferies | Buy |
Jul-13-21 | Initiated | Berenberg | Buy |
Jul-13-21 | Initiated | Canaccord Genuity | Buy |
Jul-13-21 | Initiated | Cantor Fitzgerald | Buy |
Jul-13-21 | Initiated | Citigroup | Buy |
Jul-13-21 | Initiated | Cowen | Outperform |
Jul-13-21 | Initiated | Credit Suisse | Outperform |
Jul-13-21 | Initiated | RBC Capital Mkts | Sector Perform |
Jul-08-21 | Initiated | Aegis Capital | Buy |
View All
ATAI Life Sciences N.V. Stock (ATAI) Latest News
atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression
GlobeNewswire Inc.
atai Life Sciences Announces the Publication of Beckley Psytech’s Phase 1 Study of BPL-003 in the Journal of Psychopharmacology
GlobeNewswire Inc.
Are You Looking for a Top Momentum Pick? Why atai Life Sciences N.V. (ATAI) is a Great Choice
Zacks Investment Research
Why Ulta Beauty Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Benzinga
Signet Jewelers, Dave & Buster's Entertainment, Blue Owl Capital And Other Big Stocks Moving Higher On Wednesday
Benzinga
Is Align Technology (ALGN) Stock Outpacing Its Medical Peers This Year?
Zacks Investment Research
ATAI Life Sciences N.V. Stock (ATAI) Financials Data
ATAI Life Sciences N.V. (ATAI) Revenue 2024
ATAI reported a revenue (TTM) of $314.00 thousand for the quarter ending December 31, 2023.
ATAI Life Sciences N.V. (ATAI) Net Income 2024
ATAI net income (TTM) was -$40.23 million for the quarter ending December 31, 2023, a +73.60% increase year-over-year.
ATAI Life Sciences N.V. (ATAI) Cash Flow 2024
ATAI recorded a free cash flow (TTM) of -$84.71 million for the quarter ending December 31, 2023, a +19.70% increase year-over-year.
ATAI Life Sciences N.V. (ATAI) Earnings per Share 2024
ATAI earnings per share (TTM) was -$0.28 for the quarter ending December 31, 2023, a +71.43% growth year-over-year.
About ATAI Life Sciences N.V.
Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that are focused on multiple mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a GABA/nicotinic modulator to treat cognitive impairment associated with schizophrenia; DMX-1002, an oral formulation of ibogaine for treating opioid use disorder (OUD); GRX-917, an oral formulation of a deuterated version of etifoxine for the generalized anxiety disorder treatment; and NN-101, a novel intranasal formulation of N-acetylcysteine to treat mild traumatic brain injuries. Its therapeutic candidates also comprise VLS-01, a formulation of N,N-dimethyltryptamine for treating TRD; EMP-01, an oral formulation of an 3,4-methyl enedioxy methamphetamine for the treatment of post-traumatic stress disorder; RLS-01, a formulation of Salvinorin A for TRD; KUR-101, an oral formulation of deuterated mitragynine to treat OUD; and DMX-1001, an oral formulation of noribogaine for the treatment of OUD. The company was formerly known as Adripa Holding B.V. Atai Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany.
Cap:
|
Volume (24h):